MRI Interventions has received U.S. Food and Drug Administration (FDA) clearance for ClearPoint Pursuit, the company's first internally developed therapeutic product.
ClearPoint Pursuit is a neuroaspiration device that's indicated for controlled aspiration of blood, clotted blood, cystic components of tumors, abscesses, colloid cysts, and cerebrospinal fluid using a manual syringe during surgical procedures on the ventricular system or cerebrum. It leverages the ClearPoint navigation system from MRI Interventions and is designed to be used under MRI guidance.
MRI Interventions developed Pursuit in collaboration with the Mayo Clinic, and the product is being placed under a limited market release at a select number of U.S. hospitals. The company expects to launch Pursuit commercially in the first half of 2019.
